Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Lexeo Therapeutics, Inc.

LXEO · Nasdaq · CIK 0001907108 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

16 Form 4 transaction lines observed in the same window
9 sales · 7 option, withholding, award, gift or other lines

Last qualifying purchase2024-11-25 · CHOLMONDELEY PAULA H · $104.8K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Townsend Richard NolanChief Executive Officer
▼○▼▼○
Otero Jose ManuelChief Operating Officer
▼○▼▼○
Bhalla Narinder PalChief Medical Officer
○▼○
Tamayo Louis EdwardChief Financial Officer
○▼▼
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-11-25 · CHOLMONDELEY PAULA H.

Recent Form 4 activity

0Purchases
17Sales
13Other Form 4 lines
26SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING9 sale line(s) · context only
OTHER7 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
19,246,976
Previous report
20,627,916
Avg daily volume
2,129,601
Days to cover
9.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2024-11-25CHOLMONDELEY PAULA HPurchase (P)Common Stock15,000USD 6.99USD 104,850SEC filing ↗
2023-11-07Nessi Claudio; Omega Fund VI GP Manager, Ltd.; Omega Fund VI GP, L.P.; Omega Fund VI, L.P.; Paster Anne-Mari; Stampacchia OtelloPurchase (P)Common Stock454,545USD 11.00USD 4,999,995SEC filing ↗
2023-11-07Lundbeckfond Invest A/SPurchase (P)Common Stock227,272USD 11.00USD 2,499,992SEC filing ↗
2023-11-07ENRIGHT PATRICK G; Longitude Capital Partners IV, LLC; Longitude Venture Partners IV, L.P.; Tammenoms Bakker JulietPurchase (P)Common Stock454,545USD 11.00USD 4,999,995SEC filing ↗

Form 4 evidence

30 transaction lines in the latest 365-day window; 107 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-14Townsend Richard NolanAward / grant (A)Common Stock2,306USD 2.64USD 6,088SEC filing ↗
2026-09-14Otero Jose ManuelAward / grant (A)Common Stock2,110USD 2.64USD 5,570SEC filing ↗
2026-09-14Bhalla Narinder PalAward / grant (A)Common Stock2,714USD 3.58USD 9,716SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-14Townsend Richard NolanAward / grant (A)Common Stock2,306USD 2.64USD 6,088SEC filing ↗
2026-09-14Otero Jose ManuelAward / grant (A)Common Stock2,110USD 2.64USD 5,570SEC filing ↗
2026-09-14Bhalla Narinder PalAward / grant (A)Common Stock2,714USD 3.58USD 9,716SEC filing ↗
2026-08-18Townsend Richard NolanSale (S)Common Stock3,345USD 4.95USD 16,558SEC filing ↗
2026-08-18Tamayo Louis EdwardSale (S)Common Stock4,117USD 4.91USD 20,214SEC filing ↗
2026-08-18Otero Jose ManuelSale (S)Common Stock1,304USD 4.96USD 6,468SEC filing ↗
2026-07-01Townsend Richard NolanSale (S)Common Stock25,947USD 4.48USD 116,243SEC filing ↗
2026-07-01Tamayo Louis EdwardSale (S)Common Stock4,641USD 4.49USD 20,838SEC filing ↗
2026-07-01Otero Jose ManuelSale (S)Common Stock4,666USD 4.48USD 20,904SEC filing ↗
2026-07-01Bhalla Narinder PalSale (S)Common Stock22,306USD 4.42USD 98,593SEC filing ↗
2026-06-29Townsend Richard NolanAward / grant (A)Common Stock67,000USD 0.00USD 0SEC filing ↗
2026-06-29Tamayo Louis EdwardAward / grant (A)Common Stock12,000USD 0.00USD 0SEC filing ↗
2026-06-29Otero Jose ManuelAward / grant (A)Common Stock12,060USD 0.00USD 0SEC filing ↗
2026-06-29Bhalla Narinder PalAward / grant (A)Common Stock55,000USD 0.00USD 0SEC filing ↗
2026-05-18Townsend Richard NolanSale (S)Common Stock3,342USD 5.06USD 16,911SEC filing ↗
2026-05-18Otero Jose ManuelSale (S)Common Stock1,302USD 5.07USD 6,601SEC filing ↗
2026-04-06Townsend Richard NolanSale (S)Common Stock55,000USD 5.69USD 312,950SEC filing ↗
2026-03-13Townsend Richard NolanAward / grant (A)Common Stock2,623USD 2.64USD 6,925SEC filing ↗
2026-03-13Otero Jose ManuelAward / grant (A)Common Stock5,930USD 2.64USD 15,655SEC filing ↗
2026-02-18Townsend Richard NolanSale (S)Common Stock10,173USD 6.38USD 64,904SEC filing ↗
2026-02-18Otero Jose ManuelSale (S)Common Stock3,016USD 6.40USD 19,302SEC filing ↗
2026-02-13Bhalla Narinder PalAward / grant (A)Common Stock49,500USD 0.00USD 0SEC filing ↗
2026-02-04Townsend Richard NolanAward / grant (A)Common Stock161,665USD 0.00USD 0SEC filing ↗
2026-02-04Tamayo Louis EdwardAward / grant (A)Common Stock44,665USD 0.00USD 0SEC filing ↗
2026-02-04Otero Jose ManuelAward / grant (A)Common Stock65,000USD 0.00USD 0SEC filing ↗
2025-11-18Otero Jose ManuelSale (S)Common Stock721USD 9.27USD 6,684SEC filing ↗
2025-11-18Townsend Richard NolanSale (S)Common Stock1,127USD 9.27USD 10,447SEC filing ↗
2025-11-18See Tai SandiSale (S)Common Stock386USD 9.27USD 3,578SEC filing ↗
2025-11-18Robertson JennySale (S)Common Stock549USD 9.27USD 5,089SEC filing ↗
2025-11-18Adler EricSale (S)Common Stock615USD 9.27USD 5,701SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerLXEO
CIK0001907108
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history107 transaction lines from 2023-11-07 to 2026-09-14
4 P purchase lines · 54 S sale lines · 49 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.